Sarepta Therapeutics (NQ: SRPT )
143.45
+2.96
(+2.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
All News about Sarepta Therapeutics
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_7608.jpeg?width=1200&height=800&fit=crop)
Expert Ratings for Sarepta Therapeutics
May 03, 2023
Via Benzinga
![](https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg)
![](https://mms.businesswire.com/media/20230502006063/en/943461/5/Sarepta_Therapeutics_Logo.jpg)
![](/next-assets/images/schema-image-default.png)
Sarepta Therapeutics Earnings Preview
May 01, 2023
Via Benzinga
![](https://mms.businesswire.com/media/20230428005565/en/448979/5/Sarepta_Therapeutics_Logo.jpg)
![](https://cdn.pixabay.com/photo/2018/07/15/10/44/dna-3539309_960_720.jpg)
![](/next-assets/images/schema-image-default.png)
The Latest Analyst Ratings for Sarepta Therapeutics
April 14, 2023
Via Benzinga
![](https://mms.businesswire.com/media/20230425005062/en/448979/5/Sarepta_Therapeutics_Logo.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/04/19/screenshot_2023-04-19_at_6.36.02_pm.png?width=1200&height=800&fit=crop)
Via Benzinga
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/04/13/srpt_0.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/04/13/srpt.png?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2020/09/Stock-Sarepta-Boston01-company.jpg)
![](https://investorplace.com/wp-content/uploads/2019/08/mrk-stock-1.jpg)
![](https://investorplace.com/wp-content/uploads/2023/03/artificial-intelligence-400x225-1.jpg)
![](https://investorplace.com/wp-content/uploads/2019/10/medicine.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/04/13/microscope-g5fba378d9_1920.jpg?width=1200&height=800&fit=crop)
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](https://www.newmediawire.com/media/sites/270/images/social-image.jpg)
Via NewMediaWire
![](https://mms.businesswire.com/media/20230404005793/en/448979/5/Sarepta_Therapeutics_Logo.jpg)
![](https://ml.globenewswire.com/media/745335af-3a3a-4fb5-84c0-fdedc9adf092/small/july-30-2021-rosen-logo-jpg.jpg)
![](https://g.foolcdn.com/editorial/images/727187/smart-investor-looking-for-stocks-getty.jpg)
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](https://www.newmediawire.com/media/sites/270/images/social-image.jpg)
Via NewMediaWire
![](https://mms.businesswire.com/media/20230331005448/en/448979/5/Sarepta_Therapeutics_Logo.jpg)
![](https://mms.businesswire.com/media/20230328005970/en/538768/22/BES_Mark.jpg)
![](https://investorplace.com/wp-content/uploads/2021/01/crispr-stocks.jpg)
![](https://g.foolcdn.com/editorial/images/725700/light-bulb-drawings-with-a-person-thinking.jpg)
![](https://www.newmediawire.com/media/sites/270/images/social-image.jpg)
Via NewMediaWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.